317 related articles for article (PubMed ID: 31830937)
41. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening.
Wang DR; Tang D
World J Gastroenterol; 2008 Jan; 14(4):524-31. PubMed ID: 18203283
[TBL] [Abstract][Full Text] [Related]
42. Aberrant promoter methylation of the SFRP1 gene may contribute to colorectal carcinogenesis: a meta-analysis.
Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
Tumour Biol; 2014 Sep; 35(9):9201-10. PubMed ID: 24929326
[TBL] [Abstract][Full Text] [Related]
43. Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer.
Galamb O; Kalmár A; Péterfia B; Csabai I; Bodor A; Ribli D; Krenács T; Patai ÁV; Wichmann B; Barták BK; Tóth K; Valcz G; Spisák S; Tulassay Z; Molnár B
Epigenetics; 2016 Aug; 11(8):588-602. PubMed ID: 27245242
[TBL] [Abstract][Full Text] [Related]
44. WNT antagonist, SFRP1, is Hedgehog signaling target.
Katoh Y; Katoh M
Int J Mol Med; 2006 Jan; 17(1):171-5. PubMed ID: 16328026
[TBL] [Abstract][Full Text] [Related]
45. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer.
Dallol A; Al-Maghrabi J; Buhmeida A; Gari MA; Chaudhary AG; Schulten HJ; Abuzenadah AM; Al-Ahwal MS; Sibiany A; Al-Qahtani MH
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2069-75. PubMed ID: 23010642
[TBL] [Abstract][Full Text] [Related]
46. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
47. Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer.
Nie C; Han X; Wei R; Leonteva A; Hong J; Du X; Wang J; Zhu L; Zhao Y; Xue Y; Zhou H; Tian W
BMC Cancer; 2021 May; 21(1):551. PubMed ID: 33992091
[TBL] [Abstract][Full Text] [Related]
48. The Wnt antagonist sFRP1 in colorectal tumorigenesis.
Caldwell GM; Jones C; Gensberg K; Jan S; Hardy RG; Byrd P; Chughtai S; Wallis Y; Matthews GM; Morton DG
Cancer Res; 2004 Feb; 64(3):883-8. PubMed ID: 14871816
[TBL] [Abstract][Full Text] [Related]
49. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.
Kaur P; Mani S; Cros MP; Scoazec JY; Chemin I; Hainaut P; Herceg Z
Tumour Biol; 2012 Apr; 33(2):325-36. PubMed ID: 22351518
[TBL] [Abstract][Full Text] [Related]
50. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.
Chung MT; Lai HC; Sytwu HK; Yan MD; Shih YL; Chang CC; Yu MH; Liu HS; Chu DW; Lin YW
Gynecol Oncol; 2009 Mar; 112(3):646-53. PubMed ID: 19095296
[TBL] [Abstract][Full Text] [Related]
51. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
52. Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.
Rogler A; Kendziorra E; Giedl J; Stoehr C; Taubert H; Goebell PJ; Wullich B; Stöckle M; Lehmann J; Petsch S; Hartmann A; Stoehr R
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1779-90. PubMed ID: 25732201
[TBL] [Abstract][Full Text] [Related]
53. Hypermethylation of RUNX3 but not WIF1 gene and its association with stage and nodal status of tongue cancers.
Supic G; Kozomara R; Jovic N; Zeljic K; Magic Z
Oral Dis; 2011 Nov; 17(8):794-800. PubMed ID: 21819494
[TBL] [Abstract][Full Text] [Related]
54. [Value of combined detection of ITGA4 and SFRP2 gene methylation in stool DNA in diagnosis and prognostic evaluation of colorectal tumors].
Jin H; Pang L; Li H; Xu M; Yan H; Li R
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jun; 41(6):891-897. PubMed ID: 34238742
[TBL] [Abstract][Full Text] [Related]
55. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
Roperch JP; Incitti R; Forbin S; Bard F; Mansour H; Mesli F; Baumgaertner I; Brunetti F; Sobhani I
BMC Cancer; 2013 Dec; 13():566. PubMed ID: 24289328
[TBL] [Abstract][Full Text] [Related]
56. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.
Huang Z; Li L; Wang J
Dig Dis Sci; 2007 Sep; 52(9):2287-91. PubMed ID: 17410438
[TBL] [Abstract][Full Text] [Related]
57. Myofibroblast-derived SFRP1 as potential inhibitor of colorectal carcinoma field effect.
Valcz G; Patai AV; Kalmár A; Péterfia B; Fűri I; Wichmann B; Műzes G; Sipos F; Krenács T; Mihály E; Spisák S; Molnár B; Tulassay Z
PLoS One; 2014; 9(11):e106143. PubMed ID: 25405986
[TBL] [Abstract][Full Text] [Related]
58. Promoter methylation of SFRPs gene family in cervical cancer.
Chung MT; Sytwu HK; Yan MD; Shih YL; Chang CC; Yu MH; Chu TY; Lai HC; Lin YW
Gynecol Oncol; 2009 Feb; 112(2):301-6. PubMed ID: 19038436
[TBL] [Abstract][Full Text] [Related]
59. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
[TBL] [Abstract][Full Text] [Related]
60. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
Griffiths EA; Gore SD; Hooker C; McDevitt MA; Karp JE; Smith BD; Mohammad HP; Ye Y; Herman JG; Carraway HE
Leuk Lymphoma; 2010 Sep; 51(9):1711-9. PubMed ID: 20795789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
